LXRX
Lexicon Pharmaceuticals, Inc.
Biotechnology · Healthcare · United States
1.42
close · 2026-10-30
value
24
cheaper than peers24
quality
8
stronger fundamentals8
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, latest year | -9.9% | 55 |
| cash flow yield, latest year | -10.7% | 48 |
| price to book | 3.62× | 47 |
| price to sales | 15.24× | 42 |
| cash flow yield, 3 years ago | -14.3% | 36 |
| earnings yield, 3 years ago | -43.7% | 32 |
| cash flow yield, 2 years ago | -25.7% | 31 |
| earnings yield, 2 years ago | -55.6% | 28 |
| earnings yield, 1 year ago | -44.4% | 28 |
| cash flow yield, 1 year ago | -28.5% | 25 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -40.2% | 59 |
| debt to equity | 33.9% | 35 |
| operating margin | -3835.3% | 5 |
| revenue growth | -97.6% | 2 |
4 of 4 measures available
Facts
| market cap | $632M |
| free cash flow | -$44.8M |
| employees | 81 |
| first trade | 2000-04-07 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-20 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -0.14 | -0.63 | -0.79 | -0.62 | not reported |
| free cash flow | -$67.9M | -$179.8M | -$162.4M | -$90.2M | not reported |
| net income | -$50.3M | -$200.4M | -$177.1M | -$101.9M | not reported |
| revenue | $49.8M | $31.1M | $1.2M | $139,000 | not reported |
| unusual items | not reported | not reported | not reported | $0 | $0 |